title: Taxanes in the elderly: can we gain as much and be less toxic?
abstract: Taxanes are very effective agents in several types of cancer. However, their activity is counterbalanced by side effects that could represent a limitation of their use in older cancer patients. This review aims at evaluating whether or not there are data supporting a tailored use of standard taxanes i.e. docetaxel and paclitaxel in elderly patients with the aim to increase their therapeutic index. In addition, recent data on the role of nanoparticle albumine-bound paclitaxel in breast cancer are discussed in this paper.
authors.affiliation: Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Piazza dell'Ospedale 2, 59100 Prato, Italy. lbiganzoli@usl4.toscana.it
authors.forename: Laura
authors.initials: L
authors.lastname: Biganzoli
authors.forename: Sara
authors.initials: S
authors.lastname: Licitra
authors.forename: Erica
authors.initials: E
authors.lastname: Moretti
authors.forename: Marta
authors.initials: M
authors.lastname: Pestrin
authors.forename: Elena
authors.initials: E
authors.lastname: Zafarana
authors.forename: Angelo
authors.initials: A
authors.lastname: Di Leo